Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.

ClinicalTrials.gov ID: NCT00345683

Public ClinicalTrials.gov record NCT00345683. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 7:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Single-blind, Randomized, Controlled, Multinational Study for the Evaluation of Safety of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to Monovalent Hib Control Vaccine in Healthy Infants at 2, 4, 6, and 12 to 15 Months of Age.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The booster phase of the study will evaluate the safety of Hib-MenCY-TT vaccine compared to a control group receiving licensed Hib conjugate vaccine at 12 to 15 months of age. This protocol posting deals with objectives \& outcome measures of the booster phase. The objectives \& outcome measures of the primary phase are presented in a separate protocol posting (NCT number = NCT00345579). No new recruitment will take place during this booster phase of the study. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

Study identification

NCT ID
NCT00345683
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
4,021 participants

Conditions and interventions

Eligibility (public fields only)

Age range
12 Months to 15 Months
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 2007 (Type not available)
Primary completion
Sep 2008 (Actual)
Completion
Nov 2008 (Actual)
Last update posted
Nov 29, 2016

2007 – 2008

United States locations

U.S. sites
55
U.S. states
21
U.S. cities
48
Facility City State ZIP Site status
GSK Investigational Site Birmingham Alabama 35205 —
GSK Investigational Site Birmingham Alabama 35244 —
GSK Investigational Site Benton Arkansas 72015 —
GSK Investigational Site Jonesboro Arkansas 72401 —
GSK Investigational Site Little Rock Arkansas 72205 —
GSK Investigational Site Fountain Valley California 92708 —
GSK Investigational Site Fresno California 93710 —
GSK Investigational Site Fresno California 93726 —
GSK Investigational Site Madera California 93637 —
GSK Investigational Site Slinas California 93901 —
GSK Investigational Site West Covina California 91790 —
GSK Investigational Site Boulder Colorado 80303 —
GSK Investigational Site Longmont Colorado 80501 —
GSK Investigational Site Plantation Florida 33324 —
GSK Investigational Site Nampa Idaho 208 463 3126 —
GSK Investigational Site Waukee Iowa 50263 —
GSK Investigational Site West Desmoines Iowa 50266 —
GSK Investigational Site Bardstown Kentucky 40004 —
GSK Investigational Site Lexington Kentucky 40503 —
GSK Investigational Site Bossier City Louisiana 71111 —
GSK Investigational Site Boston Massachusetts 02130 —
GSK Investigational Site Nies Michigan 49120 —
GSK Investigational Site Portage Michigan 49024 —
GSK Investigational Site Stevensville Michigan 49127 —
GSK Investigational Site Saint Paul Minnesota 55108 —
GSK Investigational Site Las Vegas Nevada 89104 —
GSK Investigational Site Ithaca New York 14850 —
GSK Investigational Site New Hartford New York 13413 —
GSK Investigational Site Syracuse New York 13210 —
GSK Investigational Site Raleigh North Carolina 27609 —
GSK Investigational Site Boardman Ohio 44512 —
GSK Investigational Site Canton Ohio 44718 —
GSK Investigational Site Cleveland Ohio 44121 —
GSK Investigational Site North Canton Ohio 44720 —
GSK Investigational Site South Euclid Ohio 44121 —
GSK Investigational Site Erie Pennsylvania 16505 —
GSK Investigational Site Greenville Pennsylvania 16125 —
GSK Investigational Site Pittsburgh Pennsylvania 15217 —
GSK Investigational Site Pittsburgh Pennsylvania 15220 —
GSK Investigational Site Pittsburgh Pennsylvania 15227 —
GSK Investigational Site Pittsburgh Pennsylvania 15236 —
GSK Investigational Site Pittsburgh Pennsylvania 15241 —
GSK Investigational Site Wexford Pennsylvania 15090 —
GSK Investigational Site Charleston South Carolina 29406 —
GSK Investigational Site Kingsport Tennessee 37660 —
GSK Investigational Site Layton Utah 84041 —
GSK Investigational Site Ogden Utah 84405 —
GSK Investigational Site Orem Utah 84057 —
GSK Investigational Site Pleasant Gorve Utah 84062 —
GSK Investigational Site Salt Lake City Utah 84109 —
GSK Investigational Site Salt Lake City Utah 84121 —
GSK Investigational Site South Jordan Utah 84095 —
GSK Investigational Site West Jordan Utah 84088 —
GSK Investigational Site Madison Wisconsin 53792 —
GSK Investigational Site Marshfield Wisconsin 54449 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00345683, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 29, 2016 · Synced Oct 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00345683 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →